A track record that speaks for itself. Post-Grant Proceedings

Leading companies trust our highly-ranked PTAB team’s experience, technical depth, and creative lawyering for a reason: our dedicated practice produces winning results in complex IPRs, PGRs, and other post-grant proceedings.


Ahead of the curve.

With extensive experience with highly specialized proceedings, we consistently deliver for our clients. We know why cases are won and lost before the PTAB, and have won numerous cases for petitioners and patent owners by “making new law.” Routinely winning high-stakes matters against top-tier firms, we have an unparalleled track record of success.

WG_Misc-6

fields a renowned litigation team, handling…PTAB inter partes reviews

Chambers USA

particular prowess in post-grant proceedings, including IPRs, acting for petitioners and patent owners alike

The Legal 500

Awards & Recognition

IPR & PGR Trials Instituted When Representing Petitioners

IPR & PGR Trials Instituted When Representing Petitioners-1

Final Written Decisions (IPR) - All Instituted Claims Unpatentable

Wolf GreenfieldStat 2

Institutions Denied When Representing Patent Owners

Wolf GreenfieldStat 3

Final Written Decisions (IPR) - All Instituted Claims Patentable

Wolf GreenfieldStat 4

All Claims Survived in Matters Resolved by PTAB

Wolf GreenfieldStat 5

Our practice’s 38 members have extensive experience handling complex USPTO proceedings, including:

  • Inter partes reviews (IPRs)
  • Post-grant reviews (PGR)
  • Reexaminations
  • Interferences
  • Parallel litigation
00-Wolff_Greenfield_7-28_0088

Why our clients “would not hesitate” to hire us again.

Wolf Greenfield’s Post-Grant Proceedings Practice features a team that’s unparalleled in its ability to pick apart technically complex cases to plot a path to success. The team quickly distills cases down to key technical issues to develop and present winning arguments.

RPX Corporation

Wolf Greenfield leverages their technical expertise, patent litigation insight and longstanding practice in front of the USPTO to provide a strong Post-Grant Proceedings Practice. While their high success rate is notable on its own, their understanding of how to utilize the practice as part of a larger litigation strategy separates them from others.

Sony Corporation of America 

We've had tremendous success with IPRs that Wolf Greenfield has filed for us, and I would not hesitate to use Wolf Greenfield for such work in the future.

Fortune 500 Electronics Company

The Wolf Greenfield team has always been exceptional in all that they have done for our company. All members of the team have responded to our questions quickly yet with careful thought given to all answers.

International Pharmaceutical Company

Strong value for the expenses. Wolf Greenfield has delivered great results for us and I feel very confident in the quality of the work the team performs for us.

NASDAQ-listed Biotech Company

Post-Grant Proceedings Experience

LiTL

Persuaded the Patent Trial and Appeal Board (PTAB) to deny five out of five petitions to institute IPRs filed by Lenovo on five different patents related to computer interface technology being asserted by our client LiTL. Some of the decisions turned on claim construction issues, while others turned on the petitioner’s failures to map the claims to the prior art. (Institution denied: IPR2021-00681, IPR2021-00786, IPR2021-00800, IPR2021-00821, IPR2021-00822).

Medy-Tox

Persuaded the PTAB to deny two Inter Partes Review petitions at the institution stage on patents related to methods of treating facial wrinkles using animal-protein-free botulinum toxin compositions.  We convinced the Board that the petitioner failed to properly demonstrate that the prior art reference relied upon satisfied a particular provision of the challenged claims. (IPR2021-01203, IPR2021-01204).

WisTa

Saved two critical patents directed to certain highly purified chemical compositions for our client WisTa, even though the European counterparts were successfully challenged by the same party. (Confirmation of all claims: IPR2018-00182 and IPR2018-00323).

SolarFlare (now part of Xilinx)

Persuaded PTAB to deny institution on two unrelated patents being asserted in litigation by our client Solarflare related to sophisticated networking technology. Denials of institution on both petitions gutted the defendants’ stay strategy, and the litigation settled within weeks on terms favorable to SolarFlare. (IPR2016-01832, IPR2016-01908).

Nuance

Successfully defended all claims of patent on medical record technology challenged by a competitor, with the result upheld on appeal to the Federal Circuit. (Confirmation of all claims: IPR2018-01355).

Enleofen, Boehringer Ingelheim and patent owners Singapore Health Services and the National University of Singapore

Successfully defended patent on groundbreaking fibrosis treatment by convincing the PTAB to deny institution of PGR filed by competitor because the petitioner failed to meet the threshold showing that any claim is likely unpatentable based on lack of written description, non-enablement or obviousness. (Institution denied: PGR2019-00053).

University of Maryland

Saved a valuable patent by demonstrating petitioner failed to show lack of written description and lack of enablement for “tagged proteins” used to treat cancer, and therefore challenged patent antedated the purported prior art references. (Institution denied: IPR2020-00233).

Saint-Gobain

Won confirmation of all claims in a patent owned by our client Saint-Gobain—marking a rare instance of a patent surviving an America Invents Act review entirely unscathed. We convinced the PTAB to reverse its initial view that the claims were likely invalid by showing that Saint-Gobain’s significant commercial success was tied to the patented invention. This was the first time the PTAB found claims patentable in an IPR based on secondary or objective factors. (Confirmation of all claims: IPR2014-00309).

BTG (now part of Boston Scientific)

Convinced the PTAB not to institute an IPR on behalf of our longtime client BTG International Inc., the manufacturer of CroFab® rattlesnake antivenom, preserving BTG’s right under a settlement agreement regarding an ITC litigation to prevent a competitor antivenom product from infringing its patent. (Institution denied: IPR2014-01269).

Cold Spring Harbor Laboratory

Convinced the PTAB not to institute four IPRs on four separate patents on behalf of our client Cold Spring Harbor Laboratory. The outcome preserved CSHL’s robust and widely licensed shRNA patent portfolio, which has generated more than $1 million in licensing revenue for the client. (Institution denied: IPR2016-00014, IPR2016-00015, IPR2016-00016, IPR2016-00017).

Smith & Nephew

Filed 16 petitions challenging 162 claims across several orthopedic surgery device patents asserted by rival Arthrex and achieved a perfect institution record on 16 out of 16 petitions for IPR on 162 of 162 claims. In the parallel litigation, these IPRs forced Arthrex to dismiss three asserted patents with prejudice, and to stay proceedings on three more asserted patents. (IPR2016-00483, IPR2016-00484, IPR2016-00485, IPR2016-00486, IPR2016-00487, IPR2016-00505, IPR2016-00506, IPR2016-00507, IPR2016-00508, IPR2016-00817, IPR2016-00818, IPR2016-00819, IPR2016-00854, IPR2016-00917, IPR2016-00918, IPR2017-00275).

Google and LG

Successfully invalidated all challenged claims in two patents on instant messaging technology asserted by Zipit Wireless. (IPR2019-01567, IPR2019-01568).

Sony

Obtained institution on all challenged claims directed to non-magnetic tape technology, then defeated rival Fujifilm’s non-contingent motion to amend the claims. All challenged claims were successfully proven unpatentable. (IPR2017-00809).

Formlabs

Filed a petition for IPR challenging a competitor's patent asserted against our client Formlabs, a 3D printing technology developer and manufacturer, and successfully proved all challenged claims were unpatentable. (IPR2017-01258).

RPX

Filed three petitions for IPRs against a patent asserted by a non-practicing entity against 29 large technology companies. The petition exposed a fatal defect in patent’s priority claim and led to dismissal of all lawsuits and disclaimer of the patent. (IPR2017-00208, IPR2017-00209, IPR2017-00212).

Epizyme

Successfully challenged key patents to pharmaceutical compounds and methods of treating non-Hodgkin’s lymphoma leading to cancellation of all challenged claims. (IPR2020-00327, IPR2020-00328).

RPX

Persuaded the PTAB to grant a motion for sanctions and subsequently a motion for attorneys’ fees filed by our client RPX Corporation, a leading provider of patent risk solutions, in three IPRs. The PTAB held that sanctions, rarely granted, were appropriate in this case since the patent owner violated a protective order in its handling of RPX’s confidential information. (Three petitions instituted on all grounds: IPR2015-01750, IPR2015-01751, IPR2015-01752).

RPX

Filed a petition on behalf of RPX Corporation that led the patent owner to disclaim its patent before the PTAB could institute a trial. An exceedingly small number of patent owners disclaim their patents before institution, making this a rare occurrence and complete victory for our client. (All patent claims cancelled: IPR2015-00736).

Sony

While defending Sony in a complex multi-respondent action before the International Trade Commission, filed IPR petitions against all three asserted patents. Our concerted attack on the patents before the ITC and in the Patent Office led the patent owner to drop the suit entirely less than two weeks before the ITC hearing was set to begin. Sony reached a favorable settlement that included withdrawal of its IPR petitions. (Favorable settlement: IPR2014-00230, IPR2014-00231, IPR2014-00229).

Bard

Led multi-firm effort to overcome rejections in reexamination of a medical device patent owned by C. R. Bard, Inc. on which there was an outstanding judgment in excess of $1 billion. Developed strategy that resulted in immediate withdrawal of the rejections and secured the judgment.

Nuance

Represented patent owner Nuance Communications, Inc. in nine reexamination proceedings arising from two different parallel litigations. All nine were resolved with all claims confirmed.

Google

Filed ex parte reexamination successfully invalidating all challenged claims of patent asserted by Cypress Lake Software on mobile GUI technology, with the rejection then being affirmed by the PTAB on appeal.

Ascion

Won final cancellation of all original claims and rejection of all added claims, ending the patent portion of a dispute between our client and a vendor. Related Litigation: Ascion LLC v. Ruoey Lung Enterprise Corp.

Cooper v. Goldfarb

Won the longest-running patent interference in USPTO history, prevailing in three Board of Patent Appeals and Interferences decisions and two Federal Circuit appeals. The resulting patent issued in 2002 and has been litigated with success.

Precision Biosciences

Successfully defended nine Precision BioSciences patents relating to CAR-T cell cancer immunotherapy in interferences by Cellectis.
Regents of the University of California v. University of Iowa Research Foundation. Won a dismissal that not only preserved our client’s valuable patent rights, but also significantly expanded the existing law and provided additional protection to all patent holders by restricting the ability of patent applicants to provoke an interference against an issued patent.

Raz v. Krieg

Represented the prevailing inventor in two related patent interferences. In the first, we prevailed in the preliminary motions period, and the other side appealed and then abandoned the appeal. In the second, the other side conceded and requested that judgment be entered in our favor.

Adimab v. Dyax

Invalidated Adimab's patent and removed an anticipatory reference as prior art by proving 11 months of diligence for Dyax. Resulted in Dyax obtaining a patent originally granted to a top competitor. Such successful long diligence showings are very rare.

Bestfoods v. Barber Foods

Developed a strategy that caused the patentee to concede the interference, resulting in a former collaborator’s patent being cancelled and allowing our client to obtain a patent on that subject matter.

Landers v. Sapolsky

Prevailed on behalf of the Massachusetts Institute of Technology on §112 grounds, as Sapolsky’s claims were not supported because they were broader in scope than the method disclosed in the specification.


Events


Past Events

Contact